Here's Why You Should Retain CONMED Stock in Your Portfolio for Now

CONMED Corporation (CNMD) is poised for growth, underpinned by its broad product portfolio, robust General Surgery segment which saw 3.6% constant currency revenue growth in Q3 2024, and a strong recurring revenue base comprising 85% of sales. The medical products manufacturer projects 19.3% earnings growth for fiscal 2025 and has a history of exceeding earnings estimates, with positive estimate revisions for 2024. Despite this, the company faces persistent challenges from supply-chain constraints, regulatory hurdles, and data security threats, contributing to its shares underperforming the industry and broader market over the past six months.

Analysis

CONMED Corporation (CNMD) presents a mixed investment profile, characterized by solid operational fundamentals juxtaposed with significant market underperformance and specific headwinds. The company's business model is anchored by a stable, recurring revenue stream, with 85% of sales derived from single-use products. Growth is driven by its General Surgery segment, which posted a 3.6% constant currency revenue increase in the third quarter of 2024, and its expanding product portfolio, bolstered by innovations like the AirSeal insufflator and the 2022 acquisition of In2Bones. Forward-looking indicators are positive, with analysts projecting 19.3% earnings growth for fiscal 2025 and a recent 1% upward revision in the 2024 consensus earnings estimate to $4.03 per share. However, these strengths are offset by the stock's 3.3% decline over the past six months, a stark contrast to the industry's 6.5% gain and the S&P 500's 14.3% rise. Key risks include persistent supply-chain constraints, regulatory hurdles for its Class II devices, cybersecurity threats, and a near-term negative impact on U.S. sales from recent hurricanes, which together justify its current Zacks #3 (Hold) rating.

Key Decisions for Investors

• Given the balance between strong projected earnings growth of 19.3% for 2025 and persistent headwinds like supply-chain issues and stock underperformance, current investors may consider holding their positions while monitoring for signs of operational execution improvements.
• Investors should scrutinize the upcoming quarterly report for confirmation that the General Surgery segment can maintain its growth trajectory and to assess the quantified impact of recent hurricanes on the U.S. foot and ankle business.
• Considering CNMD's 3.3% share price loss over the last six months, investors seeking stronger momentum in the medical device sector could evaluate the better-ranked peers mentioned in the report, such as Masimo (MASI) and Globus Medical (GMED), which have shown superior stock performance and growth outlooks.